[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NICHD Neonatal Research Network\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":151},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,70,97,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100568333","phase-3-milrinone-for-prevention-of-post-ligation-cardiac-syndrome-trial-100568333",false,"NCT06679855","Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial","MIDAS","Inclusion Criteria:\n\n* Gestational age at birth ≤27 weeks (and 6 days) and postnatal age \\\u003C 3 months at intervention\n* Invasive or non-invasive positive pressure respiratory support (does not include low flow nasal cannula)\n* Hemodynamically significant PDA with minimum transductal diameter ≥1.0 mm within 2 days of intervention\n* Decision by clinical team to proceed with PDA closure via surgical ligation or percutaneous cardiac catheterization based on clinical and echocardiography features of hemodynamic significance.\n\nExclusion Criteria:\n\n* Any major congenital malformation\n* Congenital heart disease (except small (≤1mm) muscular ventricular septal defects, or small\u002Fmoderate (\\\u003C3mm) atrial septal defect)\n* Acute renal failure defined by urine output \\\u003C 0.5 mL\u002Fkg\u002Fhour OR rise of serum creatinine by 0.3 mg\u002FdL within 48 hours OR rise of serum creatinine more than 40% above baseline serum creatinine within prior 72 hours.\n* Systemic administration of vasodilator\u002Finodilator agents\n* Prior history of arrhythmia","ALL","3 Months",{"count":19,"type":20},316,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues.\n\nThe main questions it aims to answer are:\n\n1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and\n2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.",[26],"Post-ligation Cardiac Syndrome","RECRUITING","2026-06-29",{"date":30,"type":31},"2026-07-01","ACTUAL",{"date":33,"type":31},"2025-06-13",{"date":35,"type":20},"2029-06-30",{"name":37,"class":38},"NICHD Neonatal Research Network","NETWORK",19,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100058940","follow-up-visit-of-high-risk-infants-100058940","NCT00009633","Follow-up Visit of High Risk Infants","FU","* Infants inborn at NRN centers\n* \\\u003C27 weeks gestational age\n* Infants enrolled in one or more additional NICHD NRN Follow-up studies. For infants that do not meet the inclusion criteria above, inclusion and exclusion criteria are determined by the criteria for the additional trial(s). In these cases, infants that are larger than 1,000 grams and\u002For older than 27 weeks may be included in the FU Study.\n\nNote: These inclusion criteria were changed as of 1\u002F1\u002F2008. Prior to this date, infants with birth weights between 401 and 1500 grams who were admitted to NRN NICUs within 14 days of birth were included in the database.","18 Months","26 Months",{"count":50,"type":20},68000,"OBSERVATIONAL","The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may affect infant neurodevelopment.",[54,55,56,57],"Infant, Newborn","Infant, Low Birth Weight","Infant, Small for Gestational Age","Infant, Premature",[37,59,60,61,62],"Extremely Low Birth Weight (ELBW)","Prematurity","Neurodevelopmental Outcome","Follow up studies",{"date":30,"type":31},{"date":65,"type":31},"1993-04-01",{"date":67,"type":20},"2030-03-31",{"name":37,"class":38},31,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100625013","continued-pressure-for-alveolar-protection-cpap-trial-100625013","NCT07417111","Continued Pressure for Alveolar Protection (CPAP Trial)","Continued Pressure for Alveolar Protection: A Randomized Controlled Trial (CPAP Trial)","CPAP","Inclusion Criteria:\n\n* Gestational age \\\u003C29 weeks at birth\n* PMA \\\u003C32 weeks at study entry\n* On treatment with CPAP without a rate in FiO2 \\\u003C0.25 and PEEP of 4-5 cmH2O\n* Meet stability criteria:\n* If previously intubated must be extubated ≥ 72 hours\n* \\\u003C3 self-resolving apneas (≤ 20 s) and\u002For bradycardia (\\\u003C100 bpm) in any hour over previous 6 hours\n* No episodes of apnea or bradycardia requiring intervention (oxygen\u002Fstimulation\u002Fbag and mask) for 24 hours\n* Parents\u002Flegal guardians consent for enrollment\n\nExclusion Criteria:\n\n* Major malformation\n* Neuromuscular condition that affects respiration\n* Terminal illness\n* Decision to withhold or limit support\n* Too sick to participate in opinion of Attending physician\n* Clinical shock, sepsis\n* Planned surgery during study period","31 Weeks",{"count":80,"type":20},860,[82],"NA","The objective of the CPAP Trial is to test whether extending CPAP until 34 weeks' PMA or for at least 2 additional weeks compared to weaning to a nasal canula will decrease the likelihood of bronchopulmonary dysplasia or death at 36 weeks' PMA.",[85],"Bronchopulmonary Dysplasia (BPD)",[87,76],"Continuous Positive Airway Pressure","NOT_YET_RECRUITING","2026-06-01",{"date":91,"type":31},"2026-06-02",{"date":93,"type":20},"2026-11-05",{"date":95,"type":20},"2029-01-30",{"name":37,"class":38},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":16,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":110,"conditions":111,"keywords":118,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100568106","neonatal-platelet-transfusion-threshold-trial-100568106","NCT06676904","Neonatal Platelet Transfusion Threshold Trial","NeoPlaTT","Inclusion Criteria:\n\n* Gestational age of 23 0\u002F7 to 26 6\u002F7 weeks\n* Postnatal age of \\\u003C 48 hours\n\nExclusion Criteria:\n\n* Comfort care or withdrawal of care planned\n* Neonatal alloimmune thrombocytopenia or suspected\u002Fconfirmed congenital platelet or bleeding disorder\n* Receipt of platelet transfusion\n* No receipt of Vitamin K\n* Parents\u002Fguardian decline consent",true,"1 Hour","48 Hours",{"count":108,"type":20},2433,[82],"The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0\u002F7 to 26 6\u002F7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0\u002F7 weeks' postmenstrual age (PMA).",[112,113,114,115,116,56,117],"Thrombocytopenia","Neonatal","Platelet Transfusion","Infant, Newborn, Diseases","Infant, Extremely Low Birth Weight","Thrombosis",[119,120,121],"platelet transfusion","neonatal","thrombosis","2026-03-24",{"date":124,"type":31},"2026-03-25",{"date":33,"type":31},{"date":127,"type":20},"2031-04-30",{"name":37,"class":38},20,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":150,"locationsCount":69},"100062628","generic-database-of-very-low-birth-weight-infants-100062628","NCT00063063","Generic Database of Very Low Birth Weight Infants","Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants","GDB","Inclusion Criteria:\n\n* Infants inborn at NICHD NRN centers that are:\n* 401-1000 grams birth weight, and\u002For\n* 20 0\u002F7 to 28 6\u002F7 weeks (\\\u003C29 weeks) gestational age\n* Infants enrolled in one or more additional NICHD NRN interventional trials or time-limited observational studies. For infants that do not meet the inclusion criteria above, inclusion and exclusion criteria for the Generic Database are determined by the criteria for the additional trial(s). In these cases, infants that are larger than 1,000 grams and\u002For older than 29 weeks may be included in the GDB.\n\nExclusion Criteria:\n\n* Infants \\>1,000 grams birth weight and\u002For \\>29 weeks gestational age\n\nNote: These inclusion criteria were changed as of 1\u002F1\u002F2008. Prior to this date, all infants with birth weights between 401 and 1500 grams who are admitted to NRN NICUs within 14 days of birth were included in the database.","14 Days",{"count":140,"type":20},80000,"The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is \"generic\"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.",[54,55,56,57],[37,59,60],"2026-03-12",{"date":146,"type":31},"2026-03-16",{"date":148,"type":31},"1987-04-01",{"date":67,"type":20},{"name":37,"class":38},""]